Recruiting

Urine VOC Testing

Sponsor:

Thomas Jefferson University

Code:

NCT07871656

Conditions

Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biosensor Platform

Study Details

Brief summary:

The goal of this observational study is to learn whether a urine-based test that measures volatile organic compounds (VOCs) can help detect lung cancer in people who have never smoked. The study will include adults who have never smoked, both with and without lung cancer.

The main questions it aims to answer are:

Can a urine VOC biosensor distinguish between people who have lung cancer and those who do not? Could this urine-based biomarker serve as a non-invasive approach for the early detection of lung cancer in people who are not currently eligible for standard lung cancer screening?

Researchers will compare participants with lung cancer to participants without lung cancer to determine whether the urine VOC signature can identify differences between the two groups.

Participants will:

Provide a urine sample for VOC testing. Provide health and demographic information as required by the study. Be classified into groups based on whether they have been diagnosed with lung cancer.

Conditions

Lung Cancer

Study ID

NCT07871656

Start date

Sep 15, 2026

Status verified date

Oct, 2026

Completion date

Mar 1, 2028

Anticipated

Primary completion date

Mar 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:

1. Adults over 18 years of age. Participants must be legally competent to provide informed consent.
2. Presence of a new, solid lung nodule identified on diagnostic CT chest scan ≥6mm in maximum diameter (representing indeterminate or suspicious nodules that may be due to a benign lung etiology or suspicious for primary lung cancer). If multiple lung nodules are present, the dominant lung nodule ≥6mm will be considered the index nodule.
3. Neversmoking status, defined as <100 lifetime cigarettes.
4. Confirmed or pending clinical diagnosis of either benign or malignant lung lesions, based on radiological and/or histopathological evaluation performed as part of routine care.
5. Able and willing to provide a urine sample of between 20 to 50 ml, collected in a sterile container under study supervision.
6. Able to understand the study information and provide written informed consent after adequate explanation of the study purpose, procedures, data handling, and absence of direct clinical benefit

Exclusion Criteria:

  • An individual who meets any of the following criteria will be excluded from participation in this study:

1. Pregnant or breastfeeding women. Pregnancy may alter urinary metabolite composition, potentially affecting analytical accuracy.
2. Patients with end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) <15mL/min/1.73m2 or the initiation of long-term dialysis or transplantation.
3. Previous diagnosis or treatment for any type of cancer. Prior malignancy or cancer therapy (surgery, chemotherapy, radiotherapy, biologic or immunotherapy) could influence urinary volatile compound profiles and confound results.
4. Active severe illness or other conditions that, in the opinion of the investigator, would interfere with participation or pose unnecessary risk.
5. Sample quality or collection constraints. Participants who cannot provide a urine sample within the required time window or under appropriate conditions for freezing and shipment will be excluded.

Study Design

Enrollment

87 participants

Anticipated

Interventions and Outcome Measures

Arms

Cohort 1: Lung Cancer Cases

Lung cancer cases will include patients with a specific malignant histopathology of primary lung cancer.

Cohort 2: Non-Cancer Controls

Non-cancer controls will include patients with a specific benign diagnosis (i.e. hamartoma, organizing pneumonia, granulomatous inflammation, infectious etiology with a specific organism on microbiologic studies) as well as nonspecific benign results (acute or chronic nonspecific inflammation or fibrosis).

Interventions

Biosensor Platform

The company developed a new system known as the "Biosensor Platform" (BSP). This platform integrates hardware, software, and database infrastructure designed by Early Labs. The outcomes are generated by a machine-learning algorithm powered by AI, which considers both the current and historical performance data of the biological sensors. Various controls are implemented to ensure the performance of the sensors is evaluated 100% of the time.

Primary outcome measure

  • Sensitivity of the Biosensor Platform (BSP) for Detection of Lung Cancer in the Jefferson Health Cohort [ Time Frame: Up to 24 months ]
  • Specificity of the Biosensor Platform (BSP) for Detection of Lung Cancer in the Jefferson Health Cohort [ Time Frame: Up to 24 months ]

Central Contacts and Locations

Central contacts

Locations

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

More Information

Sponsor

Thomas Jefferson University

Last update posted

Oct 13, 2026

Last verified

Oct, 2026

Keywords

  • Smoking
  • Pulmonary Nodule
  • Lung Biopsy
  • Surgical Resection

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-14. This information was provided to ClinicalTrials.gov by Thomas Jefferson University on 2026-10-13. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.